From: Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
Induction therapy (n = 40)
Median cycle (range)
4
(1–4)
Maintenance therapy (n = 35)
9
(1–54)
Response (n = 34)
CR
0 (0%)
PR
24 (70.6%)
SD
9 (26.5%)
PD
1 (2.9%)